Proshares Ultrashort Nasdaq Etf Profile
| BIS Etf | USD 16.57 0.09 0.55% |
PerformanceVery Weak
| Odds Of DistressLow
|
ProShares UltraShort is selling for under 16.57 as of the 16th of February 2025; that is 0.55% up since the beginning of the trading day. The etf's lowest day price was 16.24. ProShares UltraShort has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the funds investment objective. ProShares UltraShort is traded on NASDAQ Exchange in the United States. More on ProShares UltraShort Nasdaq
Moving together with ProShares Etf
| 0.71 | SH | ProShares Short SP500 | PairCorr |
| 0.62 | SPXU | ProShares UltraPro Short | PairCorr |
| 0.65 | SDS | ProShares UltraShort | PairCorr |
| 0.63 | SPXS | Direxion Daily SP | PairCorr |
Moving against ProShares Etf
ProShares Etf Highlights
| Thematic Ideas | (View all Themes) |
| Business Concentration | Health Care ETFs, Sector ETFs, Trading--Inverse Equity, ProShares (View all Sectors) |
| Issuer | ProShares |
| Inception Date | 2010-04-06 |
| Benchmark | Nasdaq Biotech Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 3.37 Million |
| Average Trading Valume | 7,910.4 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | J.P. Morgan Investor Services Co. |
| Advisor | ProShare Advisors LLC |
| Custodian | JPMorgan Chase Bank, N.A. |
| Distributor | SEI Investments Distribution Co. |
| Portfolio Manager | Michael Neches, Tarak Dave |
| Transfer Agent | JPMorgan Chase Bank, N.A. |
| Fiscal Year End | 31-May |
| Exchange | NASDAQ |
| Number of Constituents | 17.0 |
| Market Maker | Virtu Financial |
| Total Expense | 1.97 |
| Management Fee | 0.75 |
| Country Name | USA |
| Returns Y T D | (8.91) |
| Name | ProShares UltraShort Nasdaq Biotechnology |
| Currency Code | USD |
| Open Figi | BBG000QMCF87 |
| In Threey Volatility | 32.81 |
| 1y Volatility | 30.91 |
| 200 Day M A | 16.2403 |
| 50 Day M A | 17.2048 |
| Code | BIS |
| Updated At | 16th of February 2025 |
| Currency Name | US Dollar |
ProShares UltraShort Nasdaq [BIS] is traded in USA and was established 2010-04-06. The fund is classified under Trading--Inverse Equity category within ProShares family. The entity is thematically classified as Health Care ETFs. ProShares UltraShort currently have 8.74 M in assets under management (AUM). , while the total return for the last 3 years was -13.0%.
Check ProShares UltraShort Probability Of Bankruptcy
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on ProShares Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding ProShares Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as ProShares UltraShort Nasdaq Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Top ProShares UltraShort Nasdaq Etf Constituents
| VRTX | Vertex Pharmaceuticals | Stock | Health Care | |
| BBIO | BridgeBio Pharma | Stock | Health Care | |
| NVCR | Novocure | Stock | Health Care | |
| ITCI | Intracellular Th | Stock | Health Care | |
| TBPH | Theravance Biopharma | Stock | Health Care | |
| IOVA | Iovance Biotherapeutics | Stock | Health Care | |
| ACAD | ACADIA Pharmaceuticals | Stock | Health Care | |
| QURE | Uniqure NV | Stock | Health Care |
ProShares UltraShort Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ProShares UltraShort. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | 0.0785 | |||
| Jensen Alpha | 0.262 | |||
| Total Risk Alpha | 0.2562 | |||
| Sortino Ratio | 0.1132 |
ProShares UltraShort Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ProShares UltraShort Nasdaq. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
The market value of ProShares UltraShort is measured differently than its book value, which is the value of ProShares that is recorded on the company's balance sheet. Investors also form their own opinion of ProShares UltraShort's value that differs from its market value or its book value, called intrinsic value, which is ProShares UltraShort's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProShares UltraShort's market value can be influenced by many factors that don't directly affect ProShares UltraShort's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProShares UltraShort's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProShares UltraShort is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProShares UltraShort's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.